Lisata Therapeutics, Inc.

As of June 30, 2026, Lisata Therapeutics, Inc. carries a market capitalization of 30.64M, placing it among publicly traded companies globally. Its enterprise value stands at 19.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lisata Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Lisata Therapeutics, Inc. has 9.12M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 299.74, and the price-to-book ratio stands at 3.72.

These figures are as of June 30, 2026. The EV/Sales ratio of 199.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 19.94M versus a market cap of 30.64M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Lisata Therapeutics, Inc. maintains a current ratio of 3.69, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Lisata Therapeutics, Inc. posted a negative return on equity (ROE) of -99.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -80.81, reflecting losses generated across the asset base. The company generates approximately 4,494.38 in revenue per employee across its workforce of 22.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Lisata Therapeutics, Inc. recorded an income tax benefit of -387,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -15.01M and -14.62M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Lisata Therapeutics, Inc.'s stock has declined approximately 58.95% over the past 52 weeks. The 50-day moving average sits at 1.38, while the 200-day moving average is 2.89.

Over the twelve months ended June 30, 2026, Lisata Therapeutics, Inc. generated 100,000.00 in revenue and converted that into -14.62M in net income, yielding earnings per share of -1.64. EBITDA reached -16.36M, while operating income came in at -16.43M.

These figures are as of June 30, 2026. Total book value stands at 8.24M, with working capital of 8.03M providing operational flexibility.

Lisata Therapeutics, Inc. produced -12.32M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -12.32M - equivalent to -1.38 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -16,427.00 and net profit margin of -14,621.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -41.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.51, meaning Lisata Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lisata Therapeutics, Inc.'s most recent stock split took place on September 20, 2022 with a 15:1 split ratio.

As of June 30, 2026, Lisata Therapeutics, Inc. has an Altman Z-Score of -70.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.